<DOC>
	<DOCNO>NCT02870634</DOCNO>
	<brief_summary>Multicenter , open-label , single multiple dose-escalation pharmacokinetic study</brief_summary>
	<brief_title>Phase 1 Dose Escalation PK Study Cu ( II ) ATSM ALS/MND</brief_title>
	<detailed_description>Multicenter , open-label , phase 1 study Cu ( II ) ATSM administer orally patient wit amyotrophic lateral sclerosis/motor neuron disease . The study conduct three phase . In first two phase , dose cohort six patient participate single dose pharmacokinetic study follow 28-day repeated daily dose study establish recommend phase 2 dose ( RP2D ) . The first dose cohort treat 3 mg/day ; plan dose escalation 6 , 12 , 24 , 48 mg/day , subject observe safety assessment . In third phase study , participant treat RP2D confirm tolerability ass preliminary evidence efficacy . In dose escalation expansion cohort , first 28 day treatment assessment complete , discretion investigator patient may continue receive Cu ( II ) ATSM treatment maximum six 28-day treatment cycle .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Signed informed consent prior initiation studyspecific procedure ; Familial sporadic ALS/MND define clinically possible , probable , definite Awajishima Consensus Recommendations ; First ALS/MND symptom occur 2 year prior screen visit ; Seated FVC ≥ 70 % SNP ≥ 50 % predict value ; Not take riluzole stable dose riluzole least 4 week prior screen visit ( participant allow start take riluzole study ) ; Age 18 75 year time informed consent ; Patient competent caregiver responsible administration study drug ; Adequate bone marrow reserve , renal liver function : absolute neutrophil count ≥ 1500/µL lymphocyte count &lt; 48 % platelet count ≥ 150,000/µL hemoglobin ≥ 11 g/dL creatinine clearance ≥ 60 mL/min ( Cockroft &amp; Gault formula ) ALT and/or AST ≤ 2 x ULN total bilirubin ≤ 1.5 x ULN serum albumin ≥ 2.8 g/dL Women men partner childbearing potential must take effective contraception study woman childbearing potential must negative pregnancy test nonlactating screen Inability swallow oral medication presence GI disorder deem jeopardize intestinal absorption Cu ( II ) ATSM Dependence mechanical ventilation ( noninvasive invasive ) part day night Exposure investigational agent within 3 month two investigational agent within 6 month prior screen visit Active GI disease ( except gastrointestingal reflux disease ) within 30 day screen visit Known immune compromise illness treatment Presence follow clinical condition drug abuse alcoholism unstable cardiac , pulmonary , renal , hepatic , endocrine hematologic disorder active infectious disease AIDS AIDSrelated complex current malignancy unstable psychiatric illness , define psychosis untreated major depression within 90 day screen visit neuromuscular disease ALS/MND Dementia may affect either outcome measure patient understand and/or compliance study requirement procedure Use anticoagulant therapeutic dos within 7 day prior screen visit Current use strong inducer inhibitor CYPs 2C19 2D6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>